Phase 4Recruiting
Rezdiffra® With Concomitant Therapies Commonly Used to Treat Comorbidities in Adults With MASH and F2-F3 Fibrosis
A Phase 4, Open-label, Multi-group Study of Rezdiffra® in Combination With Concomitant Therapies Commonly Used to Treat Comorbidities in Adults With MASH and Moderate to Advanced (F2-F3) Fibrosis, Administered According to Their Approved Labeling
- Sponsor
- Madrigal Pharmaceuticals, Inc. (Industry)
- Enrollment
- 150 planned
- Conditions
- MASH - Metabolic Dysfunction-Associated Steatohepatitis
- Interventions
- Rezdiffra; Resmetirom; ACTOS/pioglitazone; FARXIGA/dapagliflozin
- Ages
- adults, older adults
- Registry
- NCT07848191
Full record on ClinicalTrials.gov
From the registry
To determine the safety of Rezdiffra (Resmetirom) when administered alongside common prescriptions for Diabetes Metellus (Farxiga/dapagliflozin \& Actos/pioglitazone)
Primary outcomes
- Number and Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)
- Number and Percentage of Participants With TEAEs by Maximum Severity
- Number and Percentage of Participants With TEAEs by Relationship to Study Medication
History
Primary completion expected
Last registry update
Started
Registered